1 / 15

Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE

Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO Lezione 2. A NOVEL INITIATIVE TO PUT EUROPE AT THE FOREFRONT OF BIOPHARMACEUTICALS INNOVATION. IMI STRATEGIC AGENDA reducing medical needs

castor-mills
Download Presentation

Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adriana Maggi DOCENTE DI BIOTECNOLOGIE FARMACOLOGICHE CORSO DI LAUREA SPECIALISTICA IN BIOTECNOLOGIE DEL FARMACO Lezione 2

  2. A NOVEL INITIATIVE TO PUT EUROPE AT THE FOREFRONT OF BIOPHARMACEUTICALS INNOVATION

  3. IMI STRATEGIC AGENDA • reducing medical needs • Supporting breakthrough of novel therapeutic avenues • Harmonizing reductionistic and systemic approaches to drug research • Optimizing R&D process • Implementing new techniques and technologies

  4. reducing medical needs • Reclassification of the etiology of important diseases and relative drugs on the basis of the molecular target • Coordinate R&D on rare and neglected diseases • Meeting therapeutic needs in gender and age related diseases

  5. Supporting breakthrough of novel therapeutic avenues • Nuclear medicine and imaging-based approaches • Extracorporeal therapies (gene surgery, tumor vaccine, stem cell therapy, tissue engineering) • Health technologies • Immunotherapies • Nucleic acid therapies • Productiontechnologies of biologicals

  6. Harmonizing reductionistic and systemic approaches to drug research • Receptor-based drug research • Signaling pathways-based drug research (dual action, multi target approach: define complexity of signalling pathways, cell specificity, intr-pathway connectivity…) • Metabolic network-based drug research ( artificial intelligence for data handling and robotics for data generation: nomenclature, data collection, defining systems of pharmacological interest, generate formats of comparable information with old drugs, set up pilot studies)

  7. Optimizing R&D process • Reshaping clinical studies • Regulatory measures for novel therapeutics • Personalized medicine • Systematic integration of patients into drug development • Correlate preclinical and clinical studies

  8. Implementing new techniques and technologies • Novel approaches in target research • API technology • Advanced formulations • Imaging • Increasing practicability of biobancks • Pharmacoinformatics to correlate in vivo, in vitro and in silico research

  9. BIOTECNOLOGIE E FARMACOLOGIA • Identificare nuovi bersagli farmacologici • Screening di farmaci • Nuovi molecole terapeutiche

  10. Identificare nuovi bersagli farmacologici • GENOMATICA • GENOMATICA FUNZIONALE • MODELLI DI MALATTIA

  11. La GENOMATICA e la ricerca di nuovi farmaci

  12. GENOMATICA: • studio del genoma* degli esseri viventi attraverso la mappatura o sequenziamento dei geni e lo studio della loro funzione • * Per genoma si intende l’intero contenuto in DNA di una cellula, geni e sequenze intrageniche incluse

  13. genoma umano Il genoma umano è costituito da 3.000.000.000 di paia di basi Diviso in 24 sequenze lineari : i cromosomi di cui 22 sono autosomi e 2 sono i cromosomi sessuali Il DNA mitocondriale è circolare e ha le dimensioni di 16569 pb

  14. Mappare i geni: • Storicamente attraverso la costruzione di mappe fisiche (identificare e ordinare marcatori lungo il cromosoma) • Attualmente con il sequenziamento

  15. mappe fisiche costruite con: • restriction mapping • FISH (Fluorescent in situ hybridization) mapping • studigeneticidi ‘linkage’ • use of sequence tagget site (STS)

More Related